The Facility of the Year Awards recognizes winners from the U.S., Ireland, the U.K. and Switzerland, including three vaccine facilities.
Back in 2007 when Japan's Eisai agreed to pay $325 million in cash for the U.S.-based Morphotek, the pharma company had high hopes for the biotech's pipeline-leading drug focused on ovarian cancer. But those hopes could not live up to a pivotal test as farletuzumab, also known as MORAb-003, failed to hit a statistically significant goalpost for progression-free survival.
With an $80 million price tag, the environmentally engineered plant gives Morphotek the capability to make its products in-house, rather than turning to outside manufacturers.
Biotech company Morphotek apparently thought the peptide platform developed by fellow Pennsylvania company TransMolecular had just the right sting against tumors for Morphotek to acquire assets
Morphotek has acquired three buildings in Exton, PA with plans to raze them and build an $80 million manufacturing facility that will make experimental drugs for clinical trials. "Ultimately, our
Morphotek has inked a deal with Human Monoclonals International to get rights to a human monoclonal IgM antibody that is specific to a cancer cell surface antigen. The company hopes to develop a lead